Background: Female steroid hormone levels and exogenous hormone use influence breast cancer risk. We investigated the association between genetic variation in the hormone metabolism and signaling pathway and mammographic density, a strong predictor of breast cancer risk.
Introduction
Mammographic density is a relative measure of the amount of epithelium and stroma in the breast, and one of the strongest known predictors of breast cancer risk (1) . Endogenous sex steroid hormone levels and exogenous hormone therapy use have been associated with increased breast cancer risk (2) . To date, 18 studies, conducted mainly among Caucasian populations, have described the association between single-nucleotide polymorphisms (SNP) in one or more hormone pathway genes (reviewed in ref. 3 ) and mammographic density and generally reported no associations. In the current study, we investigated the associations between SNPs in hormone metabolism pathway genes and mammographic density among participants of the Singapore Chinese Health Study (SCHS), a population-based prospective study initiated in 1993 in Singapore (4).
Materials and Methods

Study participants
Details of the Mammography Subcohort, who were women enrolled in both the SCHS and the Singapore Breast Screening Project (SBSP), have been described (4) . In brief, we identified 3,777 women common to the SBSP and SCHS databases through a computer linkage, and successfully retrieved mammograms of 3,702 women (98%). Of these, DNA samples were collected from 2,164 women (1,848 blood, 316 buccal; ref 4). Mammographic density was assessed by one of the authors (G. Ursin, Cancer Registry of Norway, Oslo, Norway; ref. 4) . The Institutional Review Boards at the National University of Singapore, the National Cancer Center Singapore (Singapore), the University of Southern California (Los Angeles, CA), the University of Minnesota (Minneapolis, MN) and the University of Pittsburgh (Pittsburgh, PA) had approved this study.
We selected tagging SNPs in the hormone metabolism pathway genes (see Table 1 Genotyping of 2,164 samples was conducted using the Illumina Golden Gate Assay (Illumina Inc.) at the University of Southern California Epigenome Core Facility. We excluded 126 samples whose genotyping success rates were less than 85%. Genotyping concordance based on 42 random duplicate samples was more than 99.9%. We excluded SNPs with MAF less than 0.001 or which depart significantly from Hardy-Weinberg equilibrium (P < 0.01).
Statistical analysis
We used linear regression to examine the association between SNPs and mammographic density, adjusting for age at mammogram, body mass index (BMI; kg/m 2 ) at mammogram, and dialect group (Cantonese, Hokkien). Additional adjustment for other breast cancer risk factors, including parity, menopausal status, and hormone therapy use, did not materially change the results; these risk factors were not included in the final model. The linear regression models were based on additive genetic models, in which the regression coefficients are estimates of the difference in mammographic density per copy of the minor allele of a given polymorphism. We tested whether the association between SNPs and mammographic density is modified by established determinants of mammographic density by introducing product terms and conducting Wald tests, adjusting for age, BMI, and dialect. Analyses were conducted using SAS 9.2 (SAS Inc.). All P values are 2 sided.
To summarize the overall statistical significance of the entire set of SNPs under investigation, we applied the adaptive ranked truncated product (ARTP) test of Yu and colleagues (5).
Results
We genotyped 161 SNPs in 15 hormone metabolism pathway gene regions (Table 1) . We did not observe a significant association between SNPs in the hormone metabolism genes and mammographic density in Singapore Chinese women. The overall ARTP test for the set of SNPs investigated was not significant (P ¼ 0.70; Table 1 ). For single SNP analyses, only rs4680 (COMT) had a P value less than 0.01, but this association was not statistically significant after Bonferroni adjustment. There was no evidence of effect modification by parity, menopausal status, or BMI (<25 kg/m 2 , 25 kg/m 2 ); however, the sample size for nulliparous (n ¼ 133) or premenopausal women (n ¼ 216) was limited.
Discussion
Consistent with published data (3), our results do not support hormone pathway SNPs as genetic determinants of mammographic density in Chinese women. To our knowledge, this is the first study to investigate hormone metabolism pathway genes in association with mammographic density in a large population-based study of Asians.
For SNPs with MAF of 0.2 (average MAF of all tested SNPs), we had 80% power to detect a 3.2% difference in mammographic density per minor allele, with a Bonferroni-corrected type I error rate of 5%. One limitation of the current study is that we were not able to evaluate effect modification by hormone therapy (6) due to the very low prevalence of hormone therapy use in this population. Another limitation is the incomplete tagging of the selected genes. Nonetheless, the list of hormone pathway genes and the number of investigated SNPs in the current study is by far the largest among all published studies in Asian population, which examined 2 to 25 SNPs (3, 7) .
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